Raed M. Al Rajabi, MD

Professional Background

Dr. Al-Rajabi is a Professor of medicine in the division of medical oncology at the University of Kansas Medical Center and leads the GI medical oncology group.

Dr. Al-Rajabi received his medical degree from the University of Jordan and proceeded to complete his internal medicine residency and chief residency at St. Vincent's Charity Hospital/Case Western Reserve University in Cleveland Ohio. He completed his hematology-oncology fellowship at the University of Texas health science center San Antonio. His research interests include clinical and translational research in gastrointestinal malignancies.

In 2013 moved to Kansas he worked at both the Kansas City VA and the University of Kansas Medical Center. Developed a multidisciplinary liver cancer clinic to serve affected veterans. In 2016 transitioned full-time to the University of Kansas Cancer Center to lead the GI oncology group and expanding the GI research program.

Dr. Al-Rajabi also serves as the advanced clinical informatics director at the University of Kansas Cancer Center.

• MBBS, Medicine, Univ. of Jordan
• Internship, Al Bashir Hospital, Amman, Jordan
• Pediatrcis, Jordan University Hospital, Amman, Jordan
• Other, Internal Medicine, Case Western Reserve University; St. Vincent Charity/St. Luke's Medical Center Program, Cleveland, OH
• Other, Case Western Reserve University (St. Vincent Charity/St. Luke's Medical Center Program), Cleveland , OH
• Other, University of Texas Health Science Center, San Antonio, TX

• Hematology, American Board of Internal Medicine
• Kansas State Board of Healing Arts, Kansas
• Oncology, American Board of Internal Medicine

• GI Oncology Disease Working Group, Co-Chair, 2015 - Present
• Chemotherapy and Supportive Care Council, Chemotherapy and Supportive Care Council, Co-Chair, 2014 - Present
• Southwest Oncology Group Early Therapeutics and Rare Diseases, Member, 2014 - Present
• American Society of Clinical Oncology, Member, 2011 - Present

---

Research

Overview

Dr. Al-Rajabi cultures the GI disease working group. He is very actively involved in clinical and translational GI malignancy research. With a special interest in liver cancer, biliary cancers, neuroendocrine cancers, pancreatic cancers, colorectal cancer and anal cancers. Dr. Al-Rajabi has served as PI on several therapeutic trials in the GI oncology.

• Britt, Alec, Mohyuddin, Ghulam., Rehman, Al-Rajabi, Raed. 2020. Maintenance of Stable Disease in Metastatic Perivascular Epithelioid Cell Tumor of the Liver With Single-Agent Sorafenib. American Journal of Therapeutics, 29 (2), e259-e261. https://pubmed.ncbi.nlm.nih.gov/32516142/
• Abou-Alfa, GK, Sahai, V, Hollebecque, A, Vaccaro, G, Melisi, D, Al-Rajabi, R, Pulson, AS, Board, MJ, Gallinson, D, Murphy, AG, Oh, DY, Dotan, E, Catenacci, DV, Van Cutsen, E, Ji, T, Lihou, CF, Zhen, H, Feliz, L, Vogel, A. 2020. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open- label, phase 2 study. Lancet Oncology. https://pubmed.ncbi.nlm.nih.gov/32203698/
• Mohyuddin, Ghulam., Rehman, Aziz, Muhammad, Britt, Alec, Wade, Lee, Sun, Weijing, Baranda, Joaquina., Celebre, Al-Rajabi, Raed., Moh'd Taiseer, Saeed, Anwaar, Kasi, Anup. 2020. Similar response rates and survival with PARPi treatments for patients harboring somatic versus germline BRCA mutations: A meta-analysis and systematic review. Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary. https://meetinglibrary.asco.org/record/186621/abstract |